Francisco E. Vera-Badillo

Apr 9, 2024 | europeanurology.com | Francisco E. Vera-Badillo |Markus Eckstein |Boris A. Hadaschik

Powles T, Valderrama BP, Gupta S, et al. N Engl J Med 2024;390:875–88In EV-302, patients with biomarker-unselected untreated locally advanced or metastatic urothelial carcinoma (mUC) were randomly assigned to receive either enfortumab vedotin + pembrolizumab (EV/P; 442 patients) or platinum-based chemotherapy (444 patients) [[1]Powles T. Valderrama B.P. Gupta S. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. ].